Azienda Sanitaria Locale Roma 2 — Clinical Trial Site

29 Registered trials

12 Currently recruiting

Organisation

Azienda Sanitaria Locale Roma 2

Location

Rome, Italy

Identifier

ORG-100029955

Address

Via Dei Monti Tiburtini 385, 00157, Italy

Departments

2605: U.O.C. Ematologia
Cardiologia
Cardiologist ASL RM2
Centro per le Malattie infiammatorie croniche intestinali
DH Oncologia
Divisione Ematologia Ospedale Sant'Eugenio
Gastroenterologia
Gastroenterologia ed Endoscopia
Gastroenterologia ed Endoscopia Digestiva
Gastroenterology
Hematology
Ospedale Sant’Eugenio, UOC Ematologia
U.O.C. Ematologia
U.O.C. Neurologia Stroke Unit
UOC CARDIOLOGIA - UTIC
UOC Cardiologia e UOS Emodinamica
UOC Ematologia
UOC Hematology
UOC Nephrology and Dialysis
UOC Oncologia
UOC Oncologia Interpresidio Ospedali Pertini S.Eugemio CTO
UOC Reproductive Physiopathology and Andrology
UOC Transmurale di Gastroenterologia ed Endoscopia Digestiva

Clinical trials at this site (29)

Search interface

A study to measure mirikizumab levels in breast milk of lactating participants receiving mirikizumab therapeutically for an approved indicat… Pending

2025-522362-78-00 severely active ulcerative colitis (US) and CD (Crohn’s 6
A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t… Pending

2025-523555-66-00 Myelofibrosis 5
A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa o… Pending

2025-525005-20-00 Male Infertility 6
A Multi-Stage Study to Test a New Drug in Healthy Adult Volunteers, Then in Adults with Ulcerative Colitis Recruiting

2025-522702-21-00 Ulcerative Colitis is a type of inflammatory bowel dise 4 2026-01-26
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
A Worldwide Study Testing the New Drug Olverembatinib for Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2) Recruiting

2024-511495-32-00 Chronic Phase Chronic Myeloid Leukemia 5 2025-04-16
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
COLchicine and Thiamine in Heart Failure due to Ischemic Heart Disease (COLT-HF) Recruiting

2023-506675-96-00 Heart Failure 5 2025-01-23
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Primary Myelofibrosis 5 2024-10-16
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
Comparison between single and dual therapy with drugs that inhibits platelet aggregation in patient undergoing the percutaneous left atrial … Recruiting

2024-515361-34-00 Patients with atrial fibrillation undergoing percutaneo 6 2021-10-13
Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva… Recruiting

2024-513372-18-00 Pre- and post-menopausal women with HR+/HER2- LABC or M 4 2019-10-18
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa… Ended

2024-518304-53-00 Relapsed or Refractory Multiple Myeloma (RRMM) 5 2022-02-02
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended

2024-511636-27-00 Follicular Lymphoma 5 2021-12-01
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Colorectal cancer spread at distance, RAS BRAF wild typ 4 2020-12-03
ELEVATE UC OLE: An Open-Label Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Ended

2024-515156-21-00 Ulcerative Colitis 5 2020-01-09
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended

2023-507705-34-00 Moderate to Severe Active Ulcerative Colitis 5 2025-08-29
Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis Ended

2023-506046-24-00 Ulcerative Colitis (UC) 4 2023-07-03